SG11202012570TA - Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor - Google Patents
Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptorInfo
- Publication number
- SG11202012570TA SG11202012570TA SG11202012570TA SG11202012570TA SG11202012570TA SG 11202012570T A SG11202012570T A SG 11202012570TA SG 11202012570T A SG11202012570T A SG 11202012570TA SG 11202012570T A SG11202012570T A SG 11202012570TA SG 11202012570T A SG11202012570T A SG 11202012570TA
- Authority
- SG
- Singapore
- Prior art keywords
- oxadiazoles
- muscarinic
- agonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1810245.9A GB201810245D0 (en) | 2018-06-22 | 2018-06-22 | Pharmaceutical compounds |
PCT/GB2019/051778 WO2019243850A1 (en) | 2018-06-22 | 2019-06-24 | Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012570TA true SG11202012570TA (en) | 2021-01-28 |
Family
ID=63042556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012570TA SG11202012570TA (en) | 2018-06-22 | 2019-06-24 | Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor |
Country Status (14)
Country | Link |
---|---|
US (2) | US10858352B2 (zh) |
EP (1) | EP3810607A1 (zh) |
JP (2) | JP7389762B2 (zh) |
KR (1) | KR20210024036A (zh) |
CN (1) | CN112585135A (zh) |
AU (1) | AU2019289216B2 (zh) |
BR (1) | BR112020026437A2 (zh) |
CA (1) | CA3104085A1 (zh) |
GB (1) | GB201810245D0 (zh) |
MX (1) | MX2020014156A (zh) |
SG (1) | SG11202012570TA (zh) |
TW (1) | TW202019918A (zh) |
WO (1) | WO2019243850A1 (zh) |
ZA (1) | ZA202007986B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106831541B (zh) | 2011-11-18 | 2019-09-06 | 赫普泰雅治疗有限公司 | 毒蕈碱性m1受体激动剂 |
GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
EP4041737A1 (en) | 2019-10-09 | 2022-08-17 | Novartis AG | 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists |
WO2021070090A1 (en) | 2019-10-09 | 2021-04-15 | Novartis Ag | 2-azaspiro[3.4]octane derivatives as m4 agonists |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032486A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
US7858635B2 (en) | 2005-12-22 | 2010-12-28 | Vertex Pharmaceuticals Incorporated | Spiro compounds as modulators of muscarinic receptors |
RU2008137583A (ru) | 2006-02-22 | 2010-03-27 | Вертекс Фармасьютикалз Инкорпорейшн (Us) | Спиропиперидины в качестве модуляторов мускариновых рецепторов |
CA2660903A1 (en) | 2006-08-15 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
WO2008117229A1 (en) * | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
AU2011301934A1 (en) * | 2010-09-17 | 2013-05-16 | Array Biopharma Inc. | Piperidinyl-substituted lactams as GPR 119 modulators |
ES2602039T3 (es) * | 2012-09-18 | 2017-02-17 | Heptares Therapeutics Limited | Compuestos aza bicíclicos como agonistas del receptor M1 muscarínico |
ES2694299T3 (es) * | 2013-02-07 | 2018-12-19 | Heptares Therapeutics Limited | Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4 |
EP3102568B1 (en) * | 2014-02-06 | 2018-06-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists. |
GB201404922D0 (en) * | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201513743D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201513742D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201617454D0 (en) * | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
-
2018
- 2018-06-22 GB GBGB1810245.9A patent/GB201810245D0/en not_active Ceased
-
2019
- 2019-06-24 BR BR112020026437-7A patent/BR112020026437A2/pt unknown
- 2019-06-24 TW TW108122031A patent/TW202019918A/zh unknown
- 2019-06-24 SG SG11202012570TA patent/SG11202012570TA/en unknown
- 2019-06-24 US US16/450,279 patent/US10858352B2/en active Active
- 2019-06-24 MX MX2020014156A patent/MX2020014156A/es unknown
- 2019-06-24 JP JP2020571700A patent/JP7389762B2/ja active Active
- 2019-06-24 EP EP19734158.9A patent/EP3810607A1/en active Pending
- 2019-06-24 KR KR1020217001748A patent/KR20210024036A/ko unknown
- 2019-06-24 AU AU2019289216A patent/AU2019289216B2/en active Active
- 2019-06-24 WO PCT/GB2019/051778 patent/WO2019243850A1/en active Application Filing
- 2019-06-24 CA CA3104085A patent/CA3104085A1/en active Pending
- 2019-06-24 CN CN201980054880.1A patent/CN112585135A/zh active Pending
-
2020
- 2020-10-13 US US17/069,070 patent/US11319312B2/en active Active
- 2020-12-21 ZA ZA2020/07986A patent/ZA202007986B/en unknown
-
2023
- 2023-09-22 JP JP2023158190A patent/JP2023164721A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7389762B2 (ja) | 2023-11-30 |
JP2021528447A (ja) | 2021-10-21 |
TW202019918A (zh) | 2020-06-01 |
KR20210024036A (ko) | 2021-03-04 |
CN112585135A (zh) | 2021-03-30 |
AU2019289216A1 (en) | 2021-01-14 |
US20210101893A1 (en) | 2021-04-08 |
ZA202007986B (en) | 2021-10-27 |
GB201810245D0 (en) | 2018-08-08 |
EP3810607A1 (en) | 2021-04-28 |
MX2020014156A (es) | 2021-03-09 |
CA3104085A1 (en) | 2019-12-26 |
BR112020026437A2 (pt) | 2021-03-23 |
JP2023164721A (ja) | 2023-11-10 |
AU2019289216B2 (en) | 2023-04-06 |
US20190389849A1 (en) | 2019-12-26 |
US10858352B2 (en) | 2020-12-08 |
US11319312B2 (en) | 2022-05-03 |
WO2019243850A1 (en) | 2019-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202007986B (en) | Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor | |
IL273924A (en) | Muscarinic acetylcholine M4 receptor antagonists | |
HK1248218A1 (zh) | 作為毒蕈碱m1受體和/或m4受體的激動劑的螺環化合物 | |
HK1253036A1 (zh) | 作為毒蕈碱m1和/或m4受體的激動劑的肟化合物 | |
EP3810614C0 (en) | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | |
IL274062A (en) | Muscarinic acetylcholine M4 receptor antagonists | |
IL276411A (en) | M4 muscarinic acetylcholine receptor antagonists | |
IL271805A (en) | M4 muscarinic acetylcholine receptor antagonists | |
EP3732163A4 (en) | MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4 | |
EP3697781A4 (en) | MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4 | |
EP3665175A4 (en) | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS | |
EP3762386A4 (en) | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | |
IL260720B (en) | Orexin-1 receptor inhibitors and preparations containing them | |
EP3891143C0 (en) | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | |
IL281938A (en) | Stable compositions of semaglutide and uses thereof | |
ZA202004532B (en) | Compositions for the management of hyperglycemia and related conditions | |
RS64722B1 (sr) | Heterociklično jedinjenje i njegova upotreba kao pozitivnog alosteričkog modulatora holinergičkog muskarinskog m1 receptora | |
EP3894441A4 (en) | RANK ANTAGONISTS AND THEIR USES | |
EP3662906A4 (en) | LAMININE 67 KDA RECEIVER AGONIST AND ITS USE | |
IL282142A (en) | The history of 4-pyrazine-2-ylmethyl-morpholine and its use as a medicine | |
AU2024204483A1 (en) | Adenosine receptor antagonists and uses thereof | |
GB201815215D0 (en) | Composition and use |